Lubiprostone gets FDA OK for opioid-linked constipation

04/24/2013 | Medscape (free registration)

Lubiprostone has gained widened FDA approval, making it the first oral therapy approved for opioid-linked constipation in adults who have chronic, noncancer pain. The drug was previously approved for chronic idiopathic constipation among adults and constipation associated with irritable bowel syndrome in adult women.

View Full Article in:

Medscape (free registration)

Published in Briefs: